PALO
ALTO, Calif., Jan. 4, 2024
/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a
biopharmaceutical company committed to researching, developing and
commercializing transformative therapeutics to treat high
prevalence retinal diseases, announced today that management will
present at the 42nd Annual J.P. Morgan Healthcare
Conference in San Francisco, CA on
Wednesday, January 10, 2024, at
7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
A live webcast of the presentation will be available on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the event.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high-prevalence retinal diseases. We are
focused on bringing new science to the design and manufacture of
next generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our antibody biopolymer conjugate
platform, or ABC Platform™, is at the core of Kodiak's
discovery engine. Kodiak's first investigational medicine,
tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer
conjugate explored for the treatment of retinal vascular diseases.
Kodiak's second clinical program, KSI-501, built from a
first-in-class bispecific protein targeting both IL-6 (anti-IL-6
antibody) and VEGF (VEGF-trap), is intended to treat both retinal
inflammatory and high prevalence retinal diseases. Kodiak is based
in Palo Alto, CA. For more
information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®,
ABC™, ABC Platform™ and the Kodiak logo are
registered trademarks or trademarks of Kodiak Sciences Inc. in
various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302026679.html
SOURCE Kodiak Sciences Inc.